Drug intelligence / Profile preview

SM1700

Development stage: Preclinical
Lead developer: SIMR
Modality: Small Molecules

Overview

SM1700 is an investigational small molecule drug candidate being developed by Shanghai SIMR Biotechnology (SIMR) for the treatment of various oncology indications. As of early 2024, the compound is in the IND-enabling (investigational new drug) phase of development. SIMR is a biopharmaceutical company that focuses on the discovery and development of innovative small molecule therapeutics for pain, inflammation, and cancer. While SM1700 is a key asset in SIMR's oncology pipeline, specific details regarding its molecular target and mechanism of action have not yet been publicly disclosed by the developer.

Beyond the preview

Go deeper on SM1700.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SM1700.

Explore the full profile